Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 6 20:31 · Ratings

RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44

Futu NewsDec 6 04:31 · Ratings

Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data

MT NewswiresDec 6 04:25

Express News | Edgewise Therapeutics Shares Down 2.7% in Volume Spike

BreakingsDec 6 03:35

Express News | Edgewise Therapeutics: Warning Letter by FDA to DR. Han Phan Is Unrelated to Any Edgewise Clinical Trial or Data

BreakingsDec 6 03:35

Express News | Edgewise Therapeutics- Believes Data Related to Co's Clinical Trials at Phan's Site Are Acquired & Stored in Accordance With FDA Requirements

BreakingsDec 6 03:34